🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

JMP Securities rates Werewolf Therapeutics stock Outperform, says platform 'inovative'

EditorEmilio Ghigini
Published 04/03/2024, 04:31 AM
© Reuters.
HOWL
-

On Wednesday, JMP Securities initiated coverage on Werewolf Therapeutics Inc. (NASDAQ:HOWL) stock with a Market Outperform rating and set a price target of $12.00. The firm believes that Werewolf's proprietary PREDATOR platform could mark a new chapter in the field of immunotherapy.

Werewolf Therapeutics, a biotechnology company, has been recognized for its innovative approach to cytokine-based therapies. JMP Securities' evaluation is based on a combination of discounted earnings per share and revenue multiple analysis. This assessment reflects confidence in the company's potential to overcome the challenges that have historically impeded the success of cytokine therapies in biotechnology.

The company's lead product candidate, WTX-124, has demonstrated promising differentiation in preclinical trials when compared to the administration of IL-2. These results underpin the analyst's positive outlook. Werewolf Therapeutics is also anticipated to release monotherapy dose-escalation results for WTX-124 and WTX-330 in the first half of 2024.

A strategic partnership with Jazz Pharmaceuticals (NASDAQ:JAZZ) and a strong cash position, reported at $134.3 million, further bolster the company's standing in the eyes of JMP Securities. The firm's analysis suggests that Werewolf Therapeutics' shares are currently undervalued, presenting an investment opportunity with a significant potential upside of approximately 296% and a downside risk of around 83%.

InvestingPro Insights

Werewolf Therapeutics Inc. (NASDAQ:HOWL) has caught the attention of JMP Securities, and a closer look at the company through InvestingPro's lens provides additional insights. With a market capitalization of $258.99 million, the company holds a notable position in the biotech sector. However, InvestingPro data reveals a challenging financial landscape with a negative P/E ratio of -5.72, indicating that the company is not currently profitable. This is further supported by a gross profit margin of -95.09% for the last twelve months as of Q4 2023, suggesting significant costs relative to revenue.

InvestingPro Tips highlight that Werewolf Therapeutics holds more cash than debt, which is a positive sign of financial health. Moreover, the company's liquid assets surpass its short-term obligations, providing some financial flexibility. Despite these strengths, analysts do not expect the company to be profitable this year, and a sales decline is anticipated. Yet, the stock has experienced a strong return over the last three months and an impressive 185.18% price uptick over the last six months, which may interest investors looking for growth potential in share price.

For those considering an investment in Werewolf Therapeutics, additional InvestingPro Tips can provide further guidance. There are 11 more tips available on InvestingPro, which could help investors make a more informed decision. To explore these tips and gain a deeper understanding of Werewolf Therapeutics, visit https://www.investing.com/pro/HOWL. Use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, offering even more insights to aid in your investment strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.